Guardant Health, Inc.
GHHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeGuardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The $22.69B market capitalization puts GH squarely in large-cap range for its industry. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights.
Market Cap
$22.69B
Beta
1.58
P/E (TTM)
—
P/E (Fwd)
-445.92
EPS (TTM)
$-3.50
EPS (Fwd)
$-0.38
ROE
—
ROA
-18.1%
Cash
$1.05B
Total Debt
$1.70B
Free CF
$26.6M
52W Change
138.7%
Annual Financials
Cash vs Debt
Where GH stands vs its 150-day and 200-day moving averages
As of the October 9, 2026 close, GH finished 25.30% above its 150-day moving average ($132.13) and 32.00% above its 200-day moving average ($125.42). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GH overbought or oversold?
At the October 9, 2026 close, GH's RSI(14) was 36.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Guardant Health, Inc. carries $1.70B in total debt against $1.05B in cash reserves — debt is roughly 1.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $26.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Revenue has grown from $449.5M (2022) to $982.0M (2025), reflecting a 118% increase over the period.
With a beta above 1.5, GH tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. No single metric tells the full story. Reviewing GH's risk profile alongside its fundamentals and technical indicators provides a more complete picture.